释放生物仿制药潜力：眼科案例研究

Ophthalmology Case Study Introduction Ensuring that challenges to biosimilar uptake are continuously assessed andaddressed is a critical part of unlocking their benefits. Biosimilar use is growingacross therapy areas with different specialties gaining experience and confidence.These biosimilars have also provided substantial savings for the overall healthsystem. Between 2023 and 2025, IQVIA Institute has published two reportshighlighting the importance of physician perspectives on biosimilars for theiroptimal use, especially in therapy areas where overall experience with biosimilarshas been limited. While certain challenges to the uptake of biosimilars arecommon across therapy areas, each new area provides some unique dynamics.Assessment of these dynamics can allow stakeholders to work together andensure that optimal benefits are achieved. This report presents a case study of Ophthalmologywhich saw the recent entry of aflibercept biosimilarsin 2025. Ophthalmology had also seen the entry ofranibizumab biosimilars in 2022, however, the uptake ofthe biosimilar was limited. With aflibercept biosimilarsentering this therapeutic area with the potential toreduce costs substantially, there is a need to assesschallenges that they might face. The degree of familiarityand prior experience with biosimilars is likely to behighly variable for stakeholders in the ophthalmologyspace given the prior experience with ranibizumab.This report provides a summary of the overall contextfor ophthalmology and a set of interviews with keystakeholders, including physicians, payers, and nurses,who are involved in the treatment and management ofophthalmology patients. The report aims to understandthe current state of knowledge about biosimilars acrossstakeholders and potential barriers to optimal biosimilaruse from a physician perspective in this therapy area. The report utilizes the interviews to highlight somepossible solutions to overcome challenges regardingthe variable level of knowledge and experience withbiosimilars along with other structural challenges. The study was produced independently by the IQVIAInstitute for Human Data Science. Funding for thisresearch and report has been provided by Sandoz.The contributions to this report of Jamie Pritchett atthe IQVIA Institute are gratefully acknowledged. Find Out More If you wish to receive future reports from the IQVIAInstitute for Human Data Science or join our mailing list,visit iqviainstitute.org. MURRAY AITKENExecutive DirectorIQVIA Institute for Human Data Science REFERENCING THIS REPORT Please use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. Unlocking Biosimilar Potential: Ophthalmology Case Study, February 2026.Available from www.iqviainstitute.org ©2026 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced ortransmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, withoutexpress written consent of IQVIA and the IQVIA Institute. Unlocking Biosimilar Potential: Ophthalmology Case Study Table of Contents Overview2Continued need for biosimilar sustainability5Ophthalmology treatment landscape and challenges9Ophthalmology stakeholder perspectives on biosimilars and barriers tobiosimilar adoption13Overcoming barriers to biosimilar adoption in ophthalmology15Summary and conclusion17Methodologies18References20About the authors22About the Institute24 Overview Yet despite these developments, achieving biosimilarsustainability can be challenging due to a variety offactors from lack of awareness to limited incentives,including favorable pricing rules and legislation, forshifting to biosimilars and other structural barriers.These challenges can have meaningful impacts on thefuture of the biosimilar space. At present, a potential$143Bn (55%) of LoE sales is the missed opportunitydue to lack of biosimilar pipeline activity. Lower-valueor orphan biologics often attract limited manufacturerinterest, raising concerns about insufficient competitionto maintain long-term market resilience. Theophthalmology therapy area has seen the launch ofa biosimilar which illustrates these risks to long-termmarket resilience: the first biosimilar in this field —ranibizumab — has seen comparatively low uptake,reaching only 40% penetration six quarters after launch,compared to over 50–60% for biosimilars in othertherapy areas. This low uptake was primarily driven bythe lack of a pre-filled syringe version based on expertinput. However, this situation can lead to a limitedexperience with biosimilars and can be instructive foraflibercept biosimilars, in the ophthalmology space, forwhich nine companies have already received EuropeanCommission approval. Biologic medicines have transformed the managementof chronic and complex diseases over the past twodecades, off